1Murdoch D,Keam SJ.Escitalopram:a review of its use the management of major depressive[J].Drugs,2005,65:2379-2404.
2Goman JM,Korotzer A,Su G,Efficacy comparison of escitalopram and citalopram in the theatment of major depressive disorder:pooled analysis of placebo-controlled trials[J].CNS Spectr,2002,7(Suppl):40-44.
1Owens MJ,Knight DL,Nemeroff CB.Second generation SSRIs:human monoamine transporter binding profile of escitalopram and R-fluoxetine[J].Biol Psychiatry,2001,50:345-350.
2Chen FH,Larsen MB,Sanchezc,et al.The S-enantiomer of R,S-citalopram,increases inhibitor binding to the human serotonin transporter by an allosteric mechanism.Comparison with other serotonin transporter inhibitors[J].Eur Neuropsychopharmacology,2005,15:193-198.
3Mork A,Kreilgaard M,Sanchez C.The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats[J].Neuropharmacology,2003,45:167-173.
4Sanchez C.R-citalopram attenuates anxiolytic effects of escitalopram in a rat ultrasonic vocalization model[J].Eur J Pharmacol,2003,464:155-158.
5Sanchez C,Gruca P,Papp M.R-citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress model of depression[J].Behav Pharmacol,2003,14:465-470.
6Plenge P,Mellerup ET,Laursen H.Affinity modulation of[^3H]imipramine,[^3H]paroxetine and[^3H]citalopram binding to the 5-HT transporter from brain and platelets[J].Eur J Pharmacol,1991,206:243-250.
7Fava M,Davidson KG.Definition and epidemiology of treatment resistant depression[J].Psychiatr Clin North Am,1996,19:179-200.
8Thase ME.The Concept of Remission:validity and limitations[J].JClin Psychiatry,2006,67:478-481.
9Thase ME.Evaluating antidepressant therapies:Remission as the optimal outcome[J].J Clin Psychiatry,2003,64(Suppl 13):18-25.
10Murdoch D,Keam SJ.Escitalopram:a review of its use in the management of major depressive disorder[J].Drugs,2005,65:2379-2404.
